Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Van der Velden A. W.) > Melphalan, predniso...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04785naa a2200661 4500
001		oai:lup.lub.lu.se:1686aaa9-7dd3-458b-9214-7ca95c1b0f0e
003		SwePub
008		160404s2016 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:133289284
024	7	a https://lup.lub.lu.se/record/85739672 URI
024	7	a https://doi.org/10.1182/blood-2015-11-6794152 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1332892842 URI
040		a (SwePub)lud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Zweegman, Sonja4 aut
245	1 0	a Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
264	1	b American Society of Hematology,c 2016
520		a The combination of melphalan, prednisone and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma (NDMM) who are ineligible for stem-cell transplantation. Long term treatment with thalidomide is hampered by neurotoxicity. Melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy showed promising results, without severe neuropathy emerging. We randomly assigned 668 NDMM patients, ineligible for stem-cell transplantation, between nine 4-weekly cycles of MPT followed by thalidomide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen with thalidomide being replaced by lenalidomide (MPR-R). This multicenter, open-label, randomised phase 3 trial was undertaken by HOVON and the NMSG. The primary endpoint was progression-free survival (PFS). The accrual for the study was completed in October 19, 2012. 318 patients were randomly assigned to receive MPT-T and 319 MPR-R. After a median follow up of 36 months PFS with MPT-T was 20 months (95% CI 18-23 months) versus 23 months (95% CI 19-27 months) with MPR-R (HR 0.87 [0.72-1.04], p=0.12). Response rates were similar, with ≥VGPR 47% and 45% respectively. Hematological toxicity was more pronounced with MPR-R, especially grade 3 and 4 neutropenia: 64 versus 27%. Neuropathy ≥ grade 3 was significantly higher in the MPT-T arm; 16% versus 2% in MPR-R, resulting in a significant shorter duration of maintenance therapy (5 versus 17 months in MPR-R), irrespective of age. MPR-R has no advantage over MPT-T concerning efficacy. The toxicity profile differed with clinically significant neuropathy during thalidomide maintenance versus myelosuppression with MPR.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
700	1	a van der Holt, Bronno4 aut
700	1	a Mellqvist, Ulf-Henrik4 aut
700	1	a Salomo, Morten4 aut
700	1	a Bos, Gerard M J4 aut
700	1	a Levin, Mark-David4 aut
700	1	a Visser-Wisselaar, Heleen4 aut
700	1	a Hansson, Markusu Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)hema-mha
700	1	a van der Velden, Annette W G4 aut
700	1	a Deenik, Wendy4 aut
700	1	a Gruber, Astrid4 aut
700	1	a Coenen, Juleon L L M4 aut
700	1	a Plesner, Torben4 aut
700	1	a Klein, Saskia K4 aut
700	1	a Tanis, Bea C4 aut
700	1	a Szatkowski, Damian L4 aut
700	1	a Brouwer, Rolf E4 aut
700	1	a Westerman, Matthijs4 aut
700	1	a Leys, M Rineke B L4 aut
700	1	a Sinnige, Harm A M4 aut
700	1	a Haukås, Einar4 aut
700	1	a van der Hem, Klaas G4 aut
700	1	a Durian, Marc F4 aut
700	1	a Mattijssen, E Vera J M4 aut
700	1	a van de Donk, Niels W C J4 aut
700	1	a Stevens-Kroef, Marian J P L4 aut
700	1	a Sonneveld, Pieter4 aut
700	1	a Waage, Anders4 aut
710	2	a Avdelningen för hematologi och transfusionsmedicinb Institutionen för laboratoriemedicin4 org
773	0	t Bloodd : American Society of Hematologyg 127:9, s. 1109-1116q 127:9<1109-1116x 1528-0020x 0006-4971
856	4	u http://www.ncbi.nlm.nih.gov/pubmed/26802176?dopt=Abstracty FULLTEXT
856	4	u http://dx.doi.org/10.1182/blood-2015-11-679415y FULLTEXT
856	4	u https://ashpublications.org/blood/article-pdf/127/9/1109/1395773/1109.pdf
856	4 8	u https://lup.lub.lu.se/record/8573967
856	4 8	u https://doi.org/10.1182/blood-2015-11-679415
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:133289284

Hitta via bibliotek

Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Blood

Av lärosätet: Lunds universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se